Key facts
- It has raised $10K; the latest was Seed Round in Dec 2025.
- Notable investors include LvlUp Ventures, Peachscore, H7 BioCapital, Johns Hopkins University, National Science Foundation Innovation Corps Program.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Regenova Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Regenova Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Regenova Pharmaceuticals
Operator of an antibody-drug discovery engine intended to accelerate the development of safe and effective biologic therapies for cancer and infectious diseases. The company offers an artificial intelligence (AI)-driven pipeline that predicts antibody-antigen binding and immunogenicity from sequence data, designs novel antibodies, and supports multiple stages of drug development from discovery to preclinical development, enabling pharmaceutical companies and research institutions to cut development time, reduce discovery costs, and bring new therapies faster under resource-efficient processes.
- Sector
- Healthcare
- HQ
- Dover, DE, United States
- Founded
- 2023
- Employees
- 2
- Website
- regenovapharma.com/
- Ownership
- Privately Held (backing)
Regenova Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Regenova Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Regenova Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.